Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
G M Brodeur, J Pritchard, F Berthold...
https://pubmed.ncbi.nlm.nih.gov/8336186/Actively Recruiting
Led by University of Birmingham · Updated on 2026-01-12
160
Participants Needed
23
Research Sites
N/A
Total Duration
Relapsed neuroblastoma is a common and serious childhood cancer that is difficult to treat, especially in high-risk cases where the disease returns after initial treatment or does not respond to standard therapies. This trial aims to improve survival for children aged 1 year and older with relapsed neuroblastoma by testing new combinations of treatments. It is an international, open-label, randomized phase III study designed to develop and evaluate these new therapies while also studying the biology of the disease using biomarker samples. Participants will be randomly assigned to one of two main treatment groups or enrolled in smaller dose confirmation groups testing new drug combinations. The current main treatments include combinations of dinutuximab beta, irinotecan, temozolomide, and bevacizumab given in 12 cycles every three weeks. Additional experimental groups may receive different combinations of these drugs. The trial includes a translational sub-study collecting tumor, blood, and bone marrow samples to better understand neuroblastoma and improve targeted therapies. During the study, patients will receive their assigned treatments over multiple cycles and be closely monitored for safety, treatment response, and quality of life. Researchers will perform various assessments including imaging scans, laboratory tests, and questionnaires to measure progression-free survival, side effects, and overall clinical benefit. Follow-up will continue up to five years after treatment to assess long-term outcomes and collect further data on patient health and disease progression.
CONDITIONS
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
T
Trial Coordinator
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Birmingham
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 cycles, each cycle lasting 21 days
Participants receive treatment with one of the study drug combinations for relapsed neuroblastoma.
Up to 12 treatment cycles with visits at the start of each cycle
Duration - Up to 60 months
Participants are monitored for progression-free survival, overall survival, and side effects after completing treatment.
Regular visits for assessments during follow-up period
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
G M Brodeur, J Pritchard, F Berthold...
https://pubmed.ncbi.nlm.nih.gov/8336186/University of Birmingham
Lead Sponsor